VP/SVP, Biology and Translational Science

Company Summary:

Prologue Medicines uses advances in structural predictions and large language models to functionally annotate the entire viral proteome to leverage millennia of viral evolution for the development of transformative medicines. Prologue has nominated two development candidates and is building a broad pipeline of therapeutics across several therapeutic areas. One of Prologue Medicines’ founding principles is to build an inclusive and exciting working environment that fosters personal and professional growth by ensuring that all team members contribute to and feel ownership of our scientific vision.

Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. Many of the companies Flagship has founded have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture.

Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies, and has been twice named to Fast Company’s annual list of the World’s Most Innovative Companies. Learn more about Flagship atwww.flagshippioneering.com.

Position Summary:

We are seeking an exceptional scientific leader to serve as VP/SVP, Biology & Translational Science, responsible for driving our discovery and early development strategy from target identification through IND and continue to support the program as needed through clinical development. This individual will integrate deep expertise in immunology, translational science and/or protein biologics to build a high-impact pipeline and ensure successful progression of programs into the clinic. The ideal candidate will have a proven ability to develop effective strategies and execution plans to advance early molecules through preclinical development to ensure emerging assets exhibit strong differentiation and possibility of success. They should have an excellent understanding of the landscape of immune-mediated diseases to help build a diversified pipeline.. The successful candidate will be an enthusiastic, goal-driven individual who participates as a strategic leader while fostering a culture of executional excellence.

Key Responsibilities:

Translational Science & Clinical Readiness

Define translational strategies to bridge preclinical findings to human studiesLead identification and implementation of biomarkers (PD, predictive, and safety)Ensure programs are designed with clinical endpoints and patient stratification in mindIncrease probability of clinical success through mechanism-based approaches.In collaboration with PKPD/ QSP modeling team, develop translational frameworks for AI enabled derisking of drug development path

Biologics Development (Hit ID to IND)

Lead progression of protein biologics programs from hit identification through lead optimization and IND-enabling studiesPartner cross-functionally with discovery and development teams to build out and drive comprehensive IND strategy, including pharmacology, safety, and translational packagesEnsure clear go/no-go decision frameworks across discovery and preclinical stagesProactively recognize and develop creative solutions for emerging technical and scientific issues

Discovery Biology & Target Strategy

Lead target identification, evaluation, and nomination grounded in human biology and disease relevanceDefine and drive biological hypotheses aligned with company strategy, with a focus on immunologyOversee development of robustin vitroandin vivomodels to validate targets and mechanismsBuild and prioritize a portfolio strategy for multiple differentiated biologics programs

Lea...